Abstract:Background Sarcopenia is characterized by loss of muscle mass and function and is associated with frailty, a syndrome with higher likelihood of falls, fractures, physical disability, and mortality. Both frailty and sarcopenia are known markers of shorter survival in various cancer patient populations. Low alanine aminotransferase (ALT), reflecting loss of muscle mass (sarcopenia), may be associated with greater frailty and shorter survival in multiple cancers. Objective To assess the potential association between low ALT and shorter survival among prostate cancer (PCa) patients and survivors. Design, setting, and participants This was a retrospective analysis of a historical cohort of PCa patients and survivors. Patients were defined as those still actively receiving PCa treatment, while those no longer receiving such treatment were classified as PCa survivors. Outcome measurements and statistical analysis ALT data were obtained from results for basic biochemical blood testing carried out for patients on their first hospital admission. Patients were divided into two groups: those with ALT ≥17 IU/l and those with ALT <17 IU/l. Univariate and multivariable analyses were conducted for between-group survival comparisons. Results and limitations We identified 9489 PCa records. The final study cohort with ALT data available included 4064 patients with ALT <40 IU/l. Of this cohort, 536 patients were actively receiving medical anticancer therapy for PCa. The mean age for the entire cohort was 74.6 yr (standard deviation 9.6) and the median ALT level was 19.28 IU/l; 1676 patients (41%) had low ALT (<17 IU/l). On univariate analysis, low ALT was associated with a 78% increase in mortality risk (95% confidence interval [CI] 1.62–1.97; p < 0.001). A sensitivity analysis of the 536 patients actively receiving medical anticancer treatment revealed that low ALT was associated with a 48% increase in mortality risk (95% CI 1.19–1.85; p = 0.001). In a multivariable model controlled for age, kidney disease, history of cerebrovascular event/transient ischemic attack, and baseline prostate-specific antigen, low ALT was still associated with a 35% increase in mortality risk (95% CI 1.12–1.63; p = 0.001). Limitations include the single-center, retrospective design. Conclusions Low ALT, which is indicative of sarcopenia and frailty, is associated with shorter survival among PCa patients and survivors and could potentially be used for treatment personalization. Patient summary We compared survival for prostate cancer patients and survivors according to their blood level of the protein alanine aminotransferase (ALT). Low ALT levels in the general population are associated with loss of muscle mass. We found that in our group of prostate cancer patients and survivors, the risk of death from any cause was higher for those with low ALT levels.

Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival

Association Between Low Alanine Aminotransferase Levels and Sarcopenia in Older Adults: A Cross-Sectional Study

Association of low alanine aminotransferase with loss of independence or death: A 5-year population-based cohort study

Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients

Serum Transaminases And Older Adults: Distribution And Associations With All-Cause Mortality

Relationship Between Alanine Aminotransferase Levels and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease

Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea

A Retrospective Study of 16,827 Patients over a 21-Year Period

Retrospective Analysis of 1830 Patients

Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Lower Alanine Aminotransferase Levels Are Associated with Increased All-Cause and Cardiovascular Mortality in Nonalcoholic Fatty Liver Patients.

Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker!

Effectiveness of sarcopenia screening markers in predicting out-of-hospital death in the oldest (≥80 years) older

Is Alanine Aminotransferase Associated with Osteopenia in Middle-Aged and Elderly Chinese?

Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study

Association of serum alanine aminotransferase with the risk of cardiovascular disease in middle-aged and elderly Chinese

Alanine Aminotransferase Is Associated With An Adverse Nocturnal Blood Glucose Profile In Individuals With Normal Glucose Regulation

Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications

Association of Serum Alanine Aminotransferase with Metabolic Syndrome in Middle-Aged and Elderly Chinese

Association of the Serum Transaminase with Mortality among the US Elderly Population

The Associations Between Liver Enzymes and the Risk of Metabolic Syndrome in the Elderly.